Kevin Feeley Sells 263 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 263 shares of GeneDx stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $78.39, for a total transaction of $20,616.57. Following the sale, the chief financial officer now owns 23,406 shares in the company, valued at $1,834,796.34. This represents a 1.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The stock was sold at an average price of $73.76, for a total transaction of $886,521.44.
• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total transaction of $18,248.40.
• On Monday, September 9th, Kevin Feeley sold 895 shares of GeneDx stock. The shares were sold at an average price of $33.33, for a total value of $29,830.35.

GeneDx Trading Down 2.8 %

Shares of NASDAQ WGS opened at $75.05 on Wednesday. GeneDx Holdings Corp. has a 1-year low of $1.45 and a 1-year high of $89.11. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The company has a 50-day moving average of $64.42 and a two-hundred day moving average of $42.26. The company has a market cap of $2.06 billion, a PE ratio of -24.13 and a beta of 2.03.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.25. The firm had revenue of $76.90 million for the quarter, compared to the consensus estimate of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The business’s revenue for the quarter was up 44.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.82) EPS. As a group, equities analysts expect that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

WGS has been the topic of a number of analyst reports. Craig Hallum upped their price target on GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Wells Fargo & Company upped their target price on shares of GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 30th. Finally, The Goldman Sachs Group increased their target price on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $59.33.

Institutional Trading of GeneDx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in WGS. Vanguard Group Inc. raised its position in shares of GeneDx by 4.2% during the 1st quarter. Vanguard Group Inc. now owns 707,612 shares of the company’s stock valued at $6,460,000 after acquiring an additional 28,678 shares during the last quarter. Driehaus Capital Management LLC bought a new stake in GeneDx in the second quarter valued at about $11,335,000. Fred Alger Management LLC acquired a new position in GeneDx in the third quarter valued at about $16,731,000. Geode Capital Management LLC boosted its holdings in GeneDx by 8.7% during the third quarter. Geode Capital Management LLC now owns 377,631 shares of the company’s stock worth $16,030,000 after buying an additional 30,379 shares during the last quarter. Finally, Assenagon Asset Management S.A. acquired a new position in shares of GeneDx during the 2nd quarter worth about $9,575,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.